Drug development

Diversity
#Clinical trials #Diversity #Drug development #Drug discovery #FDA #Inclusivity

Opinion: Are FDA plans enough to boost inclusivity within clinical trials?

DDW Editor Reece Armstrong examines whether recent FDA plans to boost diversity within clinical trials are enough to tackle the scale of the problem. In June this year, the US Food and Drug Administration (FDA) issued draft guidance designed to help boost the engagement of underrepresented communities within clinical trials.  … Read More

#Exclusive Content

#Biopharma #Drug development #Drug discovery #Oncology #Partnership

Sanofi and Orano invest in potential of radioligand cancer medicines 

Sanofi and Orano Med have entered into an agreement with the aim of accelerating the development of radioligand medicines.  Building on the radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand.  The new entity… Read More

#News

Woman with painful shoulder
#Clinical trials #Drug development #Drug discovery #Phase I trial

Novel pain relief drug enters Phase I trials 

The first participants have been enrolled in a first-in-human Phase I clinical trial for a nociceptin (NOP) receptor agonist, which it is hoped will treat chronic pain without the potential for abuse.   The trial will include 90 healthy volunteers and aims to demonstrate a favourable safety and… Read More

#News

Neuroscience innovation
#Drug development #Drug discovery #Neuroscience #Webinar

Watch DDW’s Neuroscience Showcase On Demand

In this free online event at 3pm BST on 24 October, hosted by DDW and co-sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector.  The showcase includes a panel discussion looking at… Read More

#News

#Clinical trial design #Clinical trials #Drug development #Drug discovery

Is disclosure non-compliance harming drug development?

Ali Pashazadeh, Founder and CEO of Treehill Partners, explores how clinical trial disclosure non-compliance is placing major pressures on clinical development, biopharma investment, and patient access to life saving therapies. Clinical trial disclosure non-compliance is rarely discussed and often ignored as a problem in the drug development sector. It is,… Read More

#Exclusive Content

#Biotherapeutics #Drug development #Tech transfer #Thermo Fisher Scientific

New listicle: Four tips for successful tech transfer

Tech transfer is all about transferring technology, knowledge, and expertise from one phase of development to another, or from one facility to another, to ensure the successful replication and scaling up of biotherapeutic products. This involves several key activities such as knowledge and process transfer, process standardisation, quality and compliance,… Read More

#News

#Biopharma #Digitalisation #Drug development #Drug discovery

How “digitally mature” is your pharma company? 

By Craig Williamson, Lead Platform Product Manager, Integrations Strategy at IDBS.   The biopharma industry is changing. Companies with mature digital approaches are achieving operational efficiencies and breakthroughs in R&D. Companies that don’t risk being left behind.   Digital maturity is not just about collecting data, but about making data truly useful:… Read More

#Exclusive Content

#Contract development and manufacturing organisations #Drug development #Events

SGS to showcase integrated drug development solutions at CPhI Milan 2024

This article is sponsored by SGS. Join SGS’s Health Science team at booth 5D82 to explore their integrated drug development solutions, from analytical testing to clinical research, formulation and manufacturing development. SGS is excited to announce its participation as an exhibitor where it will present its… Read More

#News

#Drug development #Drug discovery #Drug technology #Neuroscience #Webinar

Watch DDW’s first Neuroscience Showcase

In this free online event at 3pm BST on 24 October, hosted by DDW and sponsored by ApconiX and AxoSim, leading industry figures outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase includes a panel… Read More

Webinar date:
Co-sponsored by ApconiX and AxoSim
#News

#Drug development #Drug discovery #Drug technology #Neuroscience

Neuroscience Showcase

In this free online event, hosted by DDW and sponsored by ApconiX and AxoSim, leading industry figures will outline the areas of opportunity and challenges in the neuroscience drug discovery & development sector. The showcase will include a panel discussion looking at the use of new drug discovery and development… Read More

Webinar date:
Sponsored by ApconiX and AxoSim
#Webinars

Neuroscience innovation
#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Last chance: Driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

Boy tests his blood sugar levels at home
#Clinical trials #Diabetes #Drug development #Drug discovery #Regulatory

Bridging the gap between islet allo-transplantation and regulatory reform

Dr Rita Bottino, Director of Islet Programs at Imagine Pharma, discusses the need for regulatory reform in islet allotransplantation for type 1 diabetes.   Islet allotransplantation – the transplantation of isolated pancreatic islets from a deceased donor to a living recipient with type 1 diabetes – has emerged as a promising therapy… Read More

#Exclusive Content

Vaccine
#Clinical trials #Drug development #Funding #Immunology / Virology & Vaccines #Respiratory #Vicebio

New financing and clinical trial for RSV/hMOV bivalent vaccine

Vicebio has announced a $100 million Series B financing, which will be used to develop next-generation vaccines for respiratory viruses.   The development will utilise Vicebio’s Molecular Clamp technology, discovered at The University of Queensland. The technology stabilises viral glycoproteins in their highly immunogenic ‘prefusion’ conformation, crucial for… Read More

#News

Microbiome
#Drug development #Drug discovery #Mental health #Microbiome #Oncology

Hot off the press: Read the Fall issue of DDW now

The DDW Fall issue is out now and asks if the gut microbiome can unlock new therapeutics for mental health disorders, places a spotlight on oncology and includes a market report on the North American drug discovery hotspots. It also features an exclusive guide on… Read More

#Editor's Choice #News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

What are the latest advancements driving neuroscience drug discovery?

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News

#Amyotrophic lateral sclerosis (ALS) #CNS #Drug development #Drug discovery #Neuroscience #Webinar

Webinar on driving neuroscience drug discovery research

In this webinar on 30 September, from 3-4PM BST, hosted by DDW and sponsored by ApconiX, you will hear from Dr Isaac Klein, Chief Scientific Officer at Dewpoint Therapeutics, Dr Sam Clark, CEO of Terran Biosciences, and Professor Ruth Roberts, Co-founder and Director of Safety Science at ApconiX. Read More

#News